NCT02719574 · OUTCOME
Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation · Source last updated 2026-06-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure COUNT_OF_PARTICIPANTS
Unit Participants
Interval / dispersion Not reported
Time frame Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months) What was measured Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
Analysis population: Safety analysis set included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).
Groups in this outcome Phase 2: Cohort 1; FT-2102 (Single Agent) Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 2; FT-2102 (Single Agent) Participants with AML in morphologic CR)/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 3; FT-2102 (Single Agent) Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.
Phase 2: Cohort 7; FT-2102 (Single Agent) Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.
Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count Phase 2: Cohort 1; FT-2102 (Single Agent) 153 Phase 2: Cohort 2; FT-2102 (Single Agent) 18 Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 20 Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 21 Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 20 Phase 2: Cohort 7; FT-2102 (Single Agent) 10 Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 11
Reported measurements Hematology: Hemoglobin; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 146 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 46 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 86 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 86 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 25 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 91 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 116 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 150 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 50 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 57 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 107 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 21 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 117 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 138 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 103 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 36 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 36 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 44 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 27 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 71 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 92 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 55 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 126 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 83 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 50 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 129 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 103 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 39 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 120 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 28 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 73 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 64 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 139 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 77 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 62 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 96 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 49 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 57 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 41 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 45 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 134 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 136 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 108 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 7 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 116 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 24 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 82 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 8 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 2: Cohort 1; FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 2: Cohort 2; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 3; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 7; FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
value 146
group Id OG001
value 18
group Id OG002
value 5
group Id OG003
value 19
group Id OG004
value 20
group Id OG005
value 20
group Id OG006
value 10
group Id OG007
value 10
title Hematology: Hemoglobin; Increase (Grade <1) categories measurements
group Id OG000
value 1
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 1
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 0
title Hematology: Hemoglobin; Increase (Grade 1) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 0
title Hematology: Hemoglobin; Increase (Grade 2) categories measurements
group Id OG000
value 5
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 1
title Hematology: Hemoglobin; Increase (Grade 3) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 0
title Hematology: Hemoglobin; Increase (Grade 4) categories measurements
group Id OG000
value 5
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 1
title Hematology: Hemoglobin; Increase (Grade 3 or 4) categories measurements
group Id OG000
value 3
group Id OG001
value 3
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 1
group Id OG006
value 0
group Id OG007
value 0
title Hematology: Hemoglobin; Decrease (Grade <1) categories measurements
group Id OG000
value 17
group Id OG001
value 8
group Id OG002
value 0
group Id OG003
value 1
group Id OG004
value 0
group Id OG005
value 2
group Id OG006
value 1
group Id OG007
value 0
title Hematology: Hemoglobin; Decrease (Grade 1) categories measurements
group Id OG000
value 46
group Id OG001
value 3
group Id OG002
value 1
group Id OG003
value 7
group Id OG004
value 3
group Id OG005
value 5
group Id OG006
value 2
group Id OG007
value 2
title Hematology: Hemoglobin; Decrease (Grade 2) categories measurements
group Id OG000
value 86
group Id OG001
value 4
group Id OG002
value 4
group Id OG003
value 11
group Id OG004
value 18
group Id OG005
value 12
group Id OG006
value 7
group Id OG007
value 9
title Hematology: Hemoglobin; Decrease (Grade 3) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
group Id OG004
value 0
group Id OG005
value 0
group Id OG006
value 0
group Id OG007
value 0
title Hematology: Hemoglobin; Decrease (Grade 4) categories measurements
group Id OG000
value 86
group Id OG001
value 4
group Id OG002
value 4
group Id OG003
value 11
group Id OG004
value 18
group Id OG005
value 12
group Id OG006
value 7
group Id OG007
value 9
title Hematology: Hemoglobin; Decrease (Grade 3 or 4) Show more (12 of 144) denoms counts
group Id OG000
value 153
group Id OG001
value 18
group Id OG002
value 5
group Id OG003
value 20
group Id OG004
value 21
group Id OG005
value 20
group Id OG006
value 10
group Id OG007
value 11
units Participants
description Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death. groups
description Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
id OG000
title Phase 2: Cohort 1; FT-2102 (Single Agent)
description Participants with AML in morphologic CR)/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
id OG001
title Phase 2: Cohort 2; FT-2102 (Single Agent)
description Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
id OG002
title Phase 2: Cohort 3; FT-2102 (Single Agent)
description Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
id OG003
title Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)
description Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
id OG004
title Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)
description Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.
id OG005
title Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)
description Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.
id OG006
title Phase 2: Cohort 7; FT-2102 (Single Agent)
description Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\^2 + FT-2102 150 mg BID in continuous 28-day cycles.
id OG007
title Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
param Type COUNT_OF_PARTICIPANTS
population Description Safety analysis set included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).
reporting Status POSTED
time Frame Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)
title Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
type SECONDARY
unit Of Measure Participants Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle